A Practical Approach to the Use of Low Molecular Weight Heparins in VTE Treatment and Prophylaxis in Children and Newborns

REFERENCES

• Michelson AD, Bovill E, Monagle P, Andrew M. Antithrombotic therapy in children. Chest. 1998;114(5 Suppl):748S–769S.
   Google Scholar
• Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124(4):1001–1008.
   PubMed Web of Science ®Google Scholar
• Setty BA, O'Brien SH, Kerlin BA. Pediatric venous thromboembolism in the United States: a tertiary care complication of chronic diseases. Pediatr Blood Cancer. 2012;59(2):258–264.
   Google Scholar
• Andrew M, David M, Adams M et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83(5):1251–1257.
   PubMed Web of Science ®Google Scholar
• Sandoval JA, Sheehan MP, Stonerock CE, et al. Incidence, risk factors, and treatment patterns for deep venous thrombosis in hospitalized children: an increasing population at risk. J Vasc Surg. 2008;47(4):837–843.
   Google Scholar
• Parker RI. Thrombosis in the pediatric population. Crit Care Med. 2010;38(2 Suppl):S71–S75.
   Google Scholar
• Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest. 1995;108(4 Suppl):506S–522S.
   PubMed Web of Science ®Google Scholar
• Monagle P, Chan AK, Goldenberg NA et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e737S–e801S.
   PubMed Web of Science ®Google Scholar
• Young G. New anticoagulants in children: a review of recent studies and a look to the future. Thromb Res. 2011;127(2):70–74.
   PubMed Web of Science ®Google Scholar
• Kerlin BA, Blatt NB, Fuh B et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr. 2009;155(1):105–110, 110.
   PubMed Web of Science ®Google Scholar
• Young G. Old and new antithrombotic drugs in neonates and infants. Semin Fetal Neonatal Med. 2011;16(6):349–354.
   Google Scholar
• Chan AK, Monagle P. Updates in thrombosis in pediatrics: where are we after 20 years? Hematology Am Soc Hematol Educ Program. 2012;2012:439–443.
   Google Scholar
• Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost. 2000;26(Suppl 1):31–38.
   Google Scholar
• Bounameaux H. Unfractionated versus low-molecular-weight heparin in the treatment of venous thromboembolism. Vasc Med. 1998;3(1):41–46.
   Google Scholar
• Fareed J, Hoppensteadt D, Walenga J et al. Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet. 2003;42(12):1043–1057.
   PubMedGoogle Scholar
• Fareed J, Walenga JM, Hoppensteadt DA, Emanuele RM. Laboratory studies on the intravenous and subcutaneous administration of PK 10169 in man. Haemostasis. 1986;16(2):123–138.
   Google Scholar
• Frydman AM, Bara L, Le RY, Woler M, et al. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol. 1988;28(7):609–618.
   Google Scholar
• Trame MN, Mitchell L, Krumpel A, et al. Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. J Thromb Haemost. 2010;8(9):1950–1958.
   Google Scholar
• Couturaud F, Julian JA, Kearon C. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. Thromb Haemost. 2001;86(4):980–984.
   Google Scholar
• Schobess R, During C, Bidlingmaier C, et al. Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration. Haematologica. 2006;91(12):1701–1704.
   PubMed Web of Science ®Google Scholar
• Har KR, Young G. Pharmacokinetic- and pharmacodynamic-based antithrombotic dosing recommendations in children. Expert Rev Clin Pharmacol. 2012;5(4):389–396.
   Google Scholar
• Manco-Johnson MJ. How I treat venous thrombosis in children. Blood. 2006;107(1):21–29.
   Google Scholar
• Albisetti M, Andrew M. Low molecular weight heparin in children 4. Eur J Pediatr. 2002;161(2): 71–77.
   PubMed Web of Science ®Google Scholar
• Malowany JI, Monagle P, Knoppert DC et al. Enoxaparin for neonatal thrombosis: a call for a higher dose for neonates. Thromb Res. 2008;122(6):826–830.
   Google Scholar
• Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol. 2009;29(3):298–310.
   PubMed Web of Science ®Google Scholar
• Giordano P, Del Vecchio GC, Saracco P, et al. A practical approach to diagnosis and treatment of symptomatic thromboembolic events in children with acute lymphoblastic leukemia: recommendations of the “Coagulation Defects” AIEOP Working Group. Recent Patents Cardiovasc Drug Discov. 2007;2(1):53–62.
   Google Scholar
• Molinari AC, Saracco P, Cecinati V et al. Venous thrombosis in children: an emerging issue 3. Blood Coagul Fibrinolysis. 2011;22(5):351–361.
   Google Scholar
• Streif W, Goebel G, Chan AK, Massicotte MP. Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. Arch Dis Child Fetal Neonatal Ed. 2003;88(5):F365–F370.
   PubMed Web of Science ®Google Scholar
• Malowany JI, Knoppert DC, Chan AK, et al. Enoxaparin use in the neonatal intensive care unit: experience over 8 years. Pharmacotherapy. 2007;27(9):1263–1271.
   PubMed Web of Science ®Google Scholar
• Obaid L, Byrne PJ, Cheung PY. Compartment syndrome in an ELBW infant receiving low-molecular-weight heparins. J Pediatr. 2004;144(4):549.
   Google Scholar
• Monagle P, Chalmers E, Chan A et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):887S–968S.
   PubMed Web of Science ®Google Scholar
• Duncan SM, Massicotte MP, Ray L, et al. Topical lidocaine and the effect on enoxaparin absorption in children: a pilot study. Thromb Res. 2010;125(1):e1–e4.
   Google Scholar
• Bjerring P, Andersen PH, rendt-Nielsen L. Vascular response of human skin after analgesia with EMLA cream. Br J Anaesth. 1989;63(6):655–660.
   PubMed Web of Science ®Google Scholar
• Kearns GL, bdel-Rahman SM, Alander SW, et al. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–1167.
   PubMed Web of Science ®Google Scholar
• Frayling IM, Addison GM, Chattergee K, Meakin G. Methaemoglobinaemia in children treated with prilocaine-lignocaine cream. BMJ. 1990;301(6744):153–154.
   PubMedGoogle Scholar
• Frey B, Kehrer B. Toxic methaemoglobin concentrations in premature infants after application of a prilocaine-containing cream and peridural prilocaine. Eur J Pediatr. 1999;158(10):785–788.
   Google Scholar
• Laforest MD, Colas-Linhart N, Guiraud-Vitaux F et al. Pharmacokinetics and biodistribution of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers. Br J Haematol. 1991;77(2):201–208.
   Google Scholar
• Crary SE, Van OH, Journeycake JM. Experience with intravenous enoxaparin in critically ill infants and children. Pediatr Crit Care Med. 2008;9(6):647–649.
   Google Scholar
• Ghaleb MA, Barber N, Franklin BD, et al. Systematic review of medication errors in pediatric patients. Ann Pharmacother. 2006;40(10):1766–1776.
   PubMed Web of Science ®Google Scholar
• Ghaleb MA, Barber N, Franklin BD, Wong IC. The incidence and nature of prescribing and medication administration errors in paediatric inpatients. Arch Dis Child. 2010;95(2):113–118.
   Google Scholar
• Bauman ME, Black KL, Bauman ML, et al. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing. Thromb Res. 2009;123(6):845–847.
   Google Scholar
• Summerhayes R, Chan M, Ignjatovic V, et al. Stability and sterility of diluted enoxaparin under three different storage conditions. J Paediatr Child Health. 2011;47(5):299–301.
   Google Scholar
• Patel RP, Narkowicz C, Jacobson GA. In vitro stability of enoxaparin solutions (20 mg/mL) diluted in 4% glucose. Clin Ther. 2008;30(10):1880–1885.
   Google Scholar
• Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):141S–159S.
   PubMed Web of Science ®Google Scholar
• Massicotte P, Adams M, Marzinotto V, et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr. 1996;128(3):313–318.
   PubMed Web of Science ®Google Scholar
• Ignjatovic V, Najid S, Newall F, et al. Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children. Br J Haematol. 2010;149(5):734–738.
   Google Scholar
• Hamilton MA, Stang L, Etches WS, et al. Stability of low molecular weight heparins stored in plastic syringes. Thromb Res. 2003;112(1–2):117–119.
   Google Scholar